The Aesthetic Guide is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Sanofi-Aventis eyes U.S. pharma firms

Article-Sanofi-Aventis eyes U.S. pharma firms

Paris — France’s largest pharmaceutical firm is eyeing the acquisition of a major U.S. company, reports.

Allergan, Biogen Idec and Genzyme stocks rallied in trading on speculation that they may be Sanofi targets, according to the report.

Five people with knowledge of Paris-based Sanofi-Aventis’ inner workings say the company is in the early stages of considering such a transaction, according to the report. Sanofi-Aventis CEO Chris Viehbacher reportedly favors acquisitions as a strategy to help overcome growing competition for the company’s vaccines from makers of generic drugs.

Since Viehbacher joined the company two years ago, Sanofi has invested about $17 billion in 25 acquisitions, most of them small or mid-sized deals of $15 billion or less.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.